



Guidelines for Treatment of Urinary Tract Infections



Introduction

This document details the Michigan Hospital Medicine Safety (HMS) Consortium preferred antibiotic choices for the treatment of uncomplicated urinary tract infections localized to the bladder, and complicated urinary tract infections (catheter-associated UTI and infections extending beyond the bladder, e.g., fever or sepsis, bacteremia, pyelonephritis). The treatment recommendations highlighted in this document are not meant to be a comprehensive guideline. This guideline also addresses the appropriate management of asymptomatic bacteriuria which accounts for a substantial burden of unnecessary antimicrobial use.



Intended Use

The recommendations within this guideline are intended to address the management of positive urine cultures in hospitalized **non-pregnant** patients in a **non-ICU** setting.


This guideline is **NOT intended** for patients experiencing the following:

- Urologic procedure during hospitalization (or in 30 days prior)
- History of urinary diversion surgery and renal transplant
- Urinary stents or percutaneous nephrostomy tubes in place
- Active urologic malignancy
- Urologic obstruction during hospitalization (or in 30 days prior)
- Septic shock or febrile neutropenia



Hospital choice of preferred antibiotic among options provided should also be based on antimicrobial stewardship/infectious diseases recommendations, hospital formulary restrictions, and hospital antibiograms (especially urine antibiograms when available).

Signs/Symptoms of UTI



**Fever in age 65+: $>37.8^{\circ}\text{C}$, Fever in age 18-64: $>38.0^{\circ}\text{C}$

^In patients with spinal cord injury



Symptoms that are **NOT** indicative of a UTI include: Cloudy/dirty urine, foul-smelling urine, sediment in urine, etc¹².

SIRS Criteria



Heart rate > 90 beats/min



Temperature $< 36^{\circ}\text{C}$ or $>38^{\circ}\text{C}$



Respiratory rate > 20 breaths/min



White blood cell count $< 4,000$ or $>12,000$ cells/mm³

Asymptomatic Bacteriuria



The term asymptomatic bacteriuria refers to isolation of bacteria in a urine culture from an individual without symptoms of urinary tract infection (UTI). Asymptomatic bacteriuria is common, especially in older patients and those admitted to the hospital or in long-term care. However, most patients with asymptomatic bacteriuria have no adverse consequences and derive no benefit from antibiotic therapy¹².



National guidelines recommend **AGAINST** testing for asymptomatic bacteriuria, except in select circumstances. Do **NOT** send a urinalysis or urine culture if no urinary signs/symptoms are present or there is an alternative cause for the sign/symptom*.



If a Urine Test is Sent in the Absence of Signs/Symptoms...



Patients with a positive urine culture and/or pyuria **SHOULD NOT** be treated with antibiotics irrespective of high bacterial colony count or a multi-drug resistant organism¹².



Altered mental status without signs of systemic infection **SHOULD NOT** be treated empirically with antibiotics for 48-72 hours while working up alternative causes (e.g., medication side effects, dehydration, constipation, etc.)¹⁰. See Appendix B for algorithm regarding these patients.



**Please use clinical judgment regarding sending urine testing in patients with severe sepsis or with baseline cognitive/functional impairment with new functional decline or falls who are hemodynamically unstable without alternative etiology.*

Urinary Tract Infection

Definitions

Uncomplicated Urinary Tract Infection¹¹

Infection limited to the bladder in male or female patients not meeting criteria for complicated UTI or CA-UTI

Catheter-Associated Urinary Tract Infection (CA-UTI)

Urinary tract infection in patients **with a urinary catheter** who **do not** have symptoms indicating infection beyond the bladder (fevers, severe sepsis, pyelonephritis, bacteremia)

- Includes indwelling foley, suprapubic catheter, and intermittent straight catheter
 - This is considered a Complicated Urinary Tract Infection, but antibiotic selection is different when there are no symptoms beyond the bladder
-

Complicated Urinary Tract Infection¹¹

Patients with urinary tract infections (with or without a urinary catheter) who have symptoms indicating infection beyond the bladder, including:

- Pyelonephritis
- Bacteremia
- Signs of systemic infection (e.g., fever, severe sepsis)

Urinary Tract Infection

Antibiotic Treatment



Recommendations for Empiric Antibiotic Choice

- **Empiric antibiotic choice** should take into consideration:
 - Previous culture results
 - Prior antibiotic use
 - Antibiotic allergies
 - Local antibiograms
 - Severity of illness
- Empiric antibiotic choice **cannot** take into account scenarios that are outside the scope of these guidelines.



Recommendations for Final Antibiotic Choice

- **Final antibiotic choice** should be based on antibiotic susceptibilities of the pathogen and take into consideration patient allergies.
- For Cystitis, **avoid fluoroquinolones** when alternative agents are available¹⁵.



Important Reminders:

- Recommended **duration of treatment** is for an effective antibiotic based on culture results.
- Remember **good documentation practices at discharge**, including:
 - Start/stop dates
 - Days of therapy already completed
 - Total duration, including inpatient and outpatient therapy
 - Education for patients on their antibiotic treatment

Uncomplicated UTI Treatment Recommendations

Empiric Antibiotic Selection	Effective Duration
<i>Preferred</i>	
Nitrofurantoin ^{6,11}	5 days ¹¹
Trimethoprim-sulfamethoxazole	3 days ¹¹
IV beta-lactam transitioned to any oral agent	≤ 5 days
<i>Alternative</i>	
Fosfomycin ⁶	1 dose
Exclusively oral beta-lactam	≤ 7 days

Specific Antibiotic Considerations:

- Nitrofurantoin should be avoided in patients >65 with a creatinine clearance of < 30ml/min¹.
- There is increasing trimethoprim-sulfamethoxazole resistance among *E. coli*⁹. Consult your local antibiogram for resistance patterns.
- Fosfomycin cost per dose is high and may not be available at some retail pharmacies⁸. Additionally, Fosfomycin susceptibilities may not be routinely available as part of standard antimicrobial susceptibility testing. Fosfomycin susceptibilities have only been established for *E.coli* and *Enterococcus* species³.
- Fluoroquinolones should be reserved for uncomplicated UTI when other oral antibiotic options are not feasible because of their propensity for collateral damage (e.g., antibiotic resistance, *C.diff* infection, other adverse effects)¹⁶. In 2016, the Federal Drug Administration placed a Black Box warning to limit fluoroquinolone use in uncomplicated UTIs due to these potential side effects¹⁵.
 - When a fluoroquinolone must be used, the duration of treatment is 3 days¹¹.
- Examples of oral beta-lactams include (but are not limited to): amoxicillin-clavulanate, cephalexin, cefdinir, cefuroxime, and cefpodoxime.
- Examples of IV beta-lactams include (but are not limited to): cefazolin, ceftriaxone, cefuroxime, piperacillin-tazobactam, and ceftazidime.

CA-UTI*

Treatment Recommendations

Empiric Antibiotic Selection	Effective Duration
Ceftriaxone	7 days^{5,11} <i>For patients with recurrent or relapsed UTIs or who are slow/delayed to respond to treatment, use clinical judgement for duration, as longer durations may be appropriate in those scenarios.</i>
Nitrofurantoin	
Trimethoprim-sulfamethoxazole	
IV beta-lactam transition to any oral agent	

*Reminder: The term CA-UTI throughout this guideline refers to a UTI in a patient who has a urinary catheter who **does not** have signs/symptoms that indicate infection beyond the bladder.

Complicated UTI

Treatment Recommendations

Clinical Scenario	Empiric Antibiotic Selection
UTI without known prior resistance or septic shock	Ceftriaxone ¹¹
UTI with septic shock/in critically ill patients	Defer to local hospital selections. Consider prior hospital cultures for empiric antibiotic selection.
Duration	
• 7 days of antibiotic therapy is appropriate for most patients with rapid clinical improvement¹¹. • Oral stepdown therapy should be tailored to culture results. • Use clinical judgement for duration in the following patients where longer durations may be appropriate: ◦ Relapsed complicated UTI or delayed symptom resolution ◦ Urinary diversion/anatomic abnormalities or recent urologic surgery	

Complicated UTI Treatment Considerations



Fluoroquinolone Usage

- When a fluoroquinolone is used, the **duration of treatment is 5-7 days** unless there is a delayed response to therapy¹¹.
- Due to potential complications from PICC lines (e.g., deep vein thrombosis, catheter-associated blood stream infection)², **oral fluoroquinolones are preferred over PICC line placement for IV antibiotics** when the urinary pathogen is susceptible and there are no contraindications to fluoroquinolones.



Specific Antibiotic Considerations

- **Nitrofurantoin and Fosfomycin** should not be used for pyelonephritis, upper urinary tract infection, or in patients with bacteremia⁷.
- **Oral beta-lactams** in some studies are associated with lower efficacy and higher relapse rates compared to trimethoprim-sulfamethoxazole and fluoroquinolones in Complicated UTI^{4,11,13}. If a beta-lactam is used, the initial therapy should be IV followed by oral beta-lactam stepdown (assuming uropathogen is susceptible).



Specific Pathogen Considerations

- A shorter course of therapy (< 14 days) is not appropriate for **Staphylococcus aureus bacteremia**¹⁴, and another source of infection (outside of the genitourinary tract) should be considered.

Appendix A

Antibiotic Dosage


Antibiotic	Dose
Amoxicillin-clavulanate*	Complicated UTI: 875mg by mouth three times daily Uncomplicated UTI: 500mg by mouth twice daily
Cefazolin*	Defer to local institutional guidelines
Cefdinir*	300mg by mouth twice daily
Cefpodoxime*	Complicated UTI: 400mg by mouth twice daily Uncomplicated UTI: 100-200mg by mouth twice daily
Cephalexin*	1g by mouth three times daily (This is the suggested dose but for Uncomplicated UTI, 1-3g divided 2-4 times daily may be appropriate in certain scenarios)
Ceftriaxone	Defer to local institutional guidelines
Cefuroxime*	Complicated UTI: 500mg by mouth twice daily Uncomplicated UTI: 250-500mg by mouth twice daily
Ciprofloxacin*	Complicated UTI: 750mg by mouth twice daily Uncomplicated UTI: 500mg by mouth twice daily
Fosfomycin	One 3g dose
Gepotidacin	Uncomplicated UTI: 1500mg by mouth twice daily for 5 days
Levofloxacin*	Complicated UTI: 750mg by mouth once daily Uncomplicated UTI: 500mg by mouth once daily
Nitrofurantoin**	100mg by mouth twice daily
Trimethoprim-sulfamethoxazole	Complicated UTI: 1-2 DS tablet (160mg/800mg) by mouth twice daily Uncomplicated UTI: 1 DS tablet (160mg/800mg) by mouth twice daily

*Dose adjustment needed based on renal function

**Dose depends on disease state (Uncomplicated UTI, Complicated UTI, Pyelonephritis), severity of presentation (e.g., septic shock, severe sepsis), presence of bacteremia, and susceptibilities of the pathogen

Appendix B:

Assessing for UTI in Elderly Patients with Acutely Altered Mental Status (AMS)¹⁰



*Please use your clinical judgement in patients with baseline cognitive or functional impairment with new functional decline or falls who are hemodynamically unstable without alternative etiology.

References

1. The 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. *J Am Geriatr Soc.* 2023. doi:10.1111/jgs.18372
2. Chopra V, et al. The Problem with Peripherally Inserted Central Catheters. *JAMA.* 2012. doi:10.1001/jama.2012.12704
3. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 20th Informational Supplement. *CLSI Document M100-S21.* 2011.
4. Geyer AC, et al. Outcomes of High-Dose Oral Beta-Lactam Definitive Therapy Compared to Fluoroquinolone or Trimethoprim-Sulfamethoxazole Oral Therapy for Bacteremia Secondary to a Urinary Tract Infection. *Antimicrob Steward Healthc Epidemiol.* 2023. doi:10.1017/ash.2023.435
5. Hooton TM, et al. Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. *Clin Infect Dis.* 2010. doi:10.1086/650482
6. Huttner A, et al. Effect of 5-Day Nitrofurantoin vs Single-Day Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. *JAMA.* 2018.
7. Johnson JR, et al. Acute Pyelonephritis in Adults. *N Engl J Med.* 2018
8. Kassabian M, et al. A Cost-Effectiveness Analysis of Fosfomycin: A Single-Dose Antibiotic Therapy for Treatment of Uncomplicated Urinary Tract Infection. *Health Serv Insights.* 2022. doi:10.1177/11786329221126340
9. Kaye K, et al. Antimicrobial Resistance Trends in Urine Escherichia coli isolates from Adult and Adolescent Females in the United States from 2011 to 2019: Rising ESBL Strains and Impact on Patient Management. *Clin Infect Dis.* 2021. doi:10.1093/cid/ciab560
10. Mody L & Juthani-Mehta M. Urinary Tract Infections in Older Women: A Clinical Review. *JAMA.* 2014. doi:10.1001/jama.2014.303
11. Nelson Z, et al. Guidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults: a WikiGuidelines Group Consensus Statement. *JAMA Netw Open.* 2024. doi:10.1001/jamanetworkopen.2024.44495
12. Nicolle L, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by IDSA. *Clin Infect Dis.* 2019. Doi:10.1093/cid/ciy1121
13. Sutton JD, et al. Oral β -lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia from a Urine Source. *JAMA Netw Open.* 2020. doi:10.1001/jamanetworkopen.2020.20166
14. Tong SYC, et al. Management of Staphylococcus aureus Bacteremia. *JAMA.* 2025. doi:10.1001/jama.2025.4288
15. US Food and Drug Administration. FDA: Drug Safety Communication: FDA Advises Restricting Fluoroquinolone Antibiotic Use for Certain Uncomplicated Infections; Warns About Disabling Side Effects that Can Occur Together. May 12, 2016. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain>
16. Vaughn V, et al. The Association of Antibiotic Stewardship with Fluoroquinolone Prescribing in Michigan Hospitals: A Multi-Hospital Cohort Study. *Clin Infect Dis.* 2019. doi:10.1093/cid/ciy1102



**Blue Cross
Blue Shield
Blue Care Network
of Michigan**

Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Support for HMS is provided by Blue Cross and Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program. Although Blue Cross Blue Shield of Michigan and HMS work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.